Drug Type Oncolytic virus |
Synonyms Recombinant Human IL12/15-PDL1B Herpes Simplex Type I Oncolytic Virus, recombinant human IL12/15-PDL1B HSV-1 oncolytic virus Injection, 重组人IL12/15-PDL1B单纯疱疹I型溶瘤病毒 + [3] |
Target |
Mechanism IL-12R stimulants(Interleukin-12 receptor stimulants), IL-15Rα stimulants(Interleukin-15 receptor subunit alpha stimulants), PDL1 inhibitors(Programmed death-ligand 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationFast Track (US), Orphan Drug (US) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Intrahepatic Cholangiocarcinoma | Phase 2 | US | Virogin Biotech Ltd.Startup | 24 Jan 2024 |
Osteosarcoma | Phase 2 | CN | 27 Jul 2023 | |
Metastatic gastric adenocarcinoma | Phase 2 | CN | 06 Mar 2023 | |
Metastatic gastroesophageal adenocarcinoma | Phase 2 | CN | 06 Mar 2023 | |
Metastatic Gastric Carcinoma | Phase 2 | CN | 17 Nov 2022 | |
Cholangiocarcinoma | Phase 2 | CN | 14 May 2022 | |
Advanced Pancreatic Adenocarcinoma | Phase 2 | CN | 08 Mar 2022 | |
Hepatocellular Carcinoma | Phase 2 | - | Virogin Biotech Ltd.Startup | 04 Feb 2022 |
Liver Cancer | Phase 1 | CN | Virogin Biotech Ltd.Startup | 23 Apr 2021 |
Advanced Malignant Solid Neoplasm | Phase 1 | CN | 24 Mar 2021 |
Phase 1 | - | 44 | VG161 expressing IL12, IL15/IL15 receptor α unit, and PD-L1 blocking peptide | ybepfjevkd(ycnnwaenro) = The most common Treatment-Related Adverse Events (TRAEs) was fever, which was resolved with symptomatic treatment ksuqvpknkq (khjdzllwrb ) | Positive | 24 May 2024 |